US Patent

US11202767 — Methods of treating urea cycle disorders and maple syrup urine disease

Method of Use · Assigned to Acer Therapeutics Inc · Expires 2036-10-17 · 10y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating urea cycle disorders and Maple Syrup Urine Disease.

USPTO Abstract

The present invention provides methods for the treatment of urea cycle disorders and Maple Syrup Urine Disease.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3502 — sodium-phenylbutyrate
U-3502 — sodium-phenylbutyrate
U-3502 — sodium-phenylbutyrate
U-3502 — sodium-phenylbutyrate
U-3502 — sodium-phenylbutyrate
U-3502 — sodium-phenylbutyrate
U-3502 — sodium-phenylbutyrate
U-3502 — sodium-phenylbutyrate

Patent Metadata

Patent number
US11202767
Jurisdiction
US
Classification
Method of Use
Expires
2036-10-17
Drug substance claim
No
Drug product claim
No
Assignee
Acer Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.